Melinta Therapeutics
The Antibiotics Company

January 10, 2018

Dan Wechsler, CEO
Cautionary Note Regarding Forward-looking Statements

• This presentation contains forward-looking statements that involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

• You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. We are under no obligation (and expressly disclaim any such obligation) to update or revise any forward-looking statement that may be made from time to time, whether as a result of new information, future developments or otherwise.

• Risks and uncertainties for Melinta Therapeutics, Inc. (the “Company”) are more fully described in the Company's filings with the SEC, including in its most recently filed Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its definitive proxy statements filed with the SEC in October and December 2017.
Creating a Pure-play Antibiotics Leader

- Founded on Nobel Prize-winning discovery
- Received 1st FDA approval (Baxdela)
- Reverse merged in 2017 to list on Nasdaq (MLNT) with >$150 million of capital
- Acquired three marketed antibiotics and pipeline
- Added strong ID-focused team

Leading Pure-play Antibiotics Pipeline from Discovery to Commercial; Significant Antibiotics-focused Talent Within Single Organization; >$1 Billion US Peak Sales Potential From 4 Currently Approved Products
The New Melinta

Products
Pipeline
Operational Strength
Discovery
Significant Commercial Opportunity
>$1 Billion US Sales Potential for Current Indications

For ABSSSI patients at risk for mixed infections in the hospital, community or ED

For cUTI in the hospital

For Gram (+) ABSSSI in the ED or community

For Acinetobacter in the hospital

Unique Market Value for Each Approved Product Optimized by Company Infrastructure and Commitment to Antibiotics
<table>
<thead>
<tr>
<th>PRODUCT/INDICATION</th>
<th>PRE CLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>NDA Submitted</th>
<th>FDA Approved</th>
<th>EMA Submitted</th>
<th>EMA Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baxdela Acute Bacterial Skin and Skin Structure Infections (ABSSSI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vabomere Complicated Urinary Tract Infections (cUTI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orbactiv ABSSSI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minocin IV Serious infections due to select organisms including Acinetobacter</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baxdela Community-acquired Bacterial Pneumonia (CABP)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fusidic Acid ABSSSI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solithromycin CABP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radezolid Dermatology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESKAPE “Superbugs”</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

>$1 Billion US Sales Potential

Industry Leading Pipeline to Fuel Future Growth
Successful Out-licensing Offers Potential to Expand Partnerships Across Full Portfolio of Assets

Global rights to products acquired from The Medicines Company present strong future partnership opportunities
Nobel Prize-winning Discovery Platform

We own the 3D structure of ribosome (home to >50% of commercial antibiotic classes)

We created the tools and developed the know-how to exploit the ribosome structure

This technology platform enables us to:

1. Engineer improvements in existing classes
2. Create novel classes of antibiotics to overcome multidrug-resistant bacteria

Discovered Radezolid, Currently in Clinical Development for Dermatology; >10,000 Compounds Created, with 3 Completely New Classes
Strong Commercial and Medical Affairs Capabilities

Commercial
- Approx. 135 sales representatives selling today
- Significant experience: ~15 years hospital + antibiotics
- A portfolio of products that allows HCPs to address serious infections across continuum of care

Medical Affairs
- More than 3x increase in field-based medical support from ID specialists
- Commitment to antibiotic stewardship
- Appropriate capital to generate and publish data for appropriate access

Leveraging Best Practices and Talent From All Organizations
### Experienced, Leading Combined Management Team

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Wechsler</td>
<td>CEO</td>
<td>&gt;25 years; led Zyvox at Pharmacia; led pharma, generics and OTC at Bausch &amp; Lomb; CEO at Smile Brands</td>
</tr>
<tr>
<td>Paul Estrem</td>
<td>CFO</td>
<td>&gt;25 years; CFO of multiple business units at Baxter</td>
</tr>
<tr>
<td>Sue Cammarata, M.D.</td>
<td>CMO</td>
<td>&gt;20 years; development of Cubicin and Zyvox</td>
</tr>
<tr>
<td>Erin Duffy, Ph.D.</td>
<td>CSO</td>
<td>&gt;20 years; leading expert in structure &amp; function of bacterial ribosome</td>
</tr>
<tr>
<td>Juliet Agranoff</td>
<td>SVP, HR</td>
<td>&gt;20 years; head of HR for The Medicines Company ID franchise</td>
</tr>
<tr>
<td>Lisa DeFrancesco</td>
<td>SVP, IR</td>
<td>&gt;15 years; VP investor relations at Allergan</td>
</tr>
<tr>
<td>Peter Di Roma</td>
<td>SVP, QA/RA</td>
<td>&gt;20 years; regulatory approval of Zyvox and Baxdela</td>
</tr>
<tr>
<td>Michael McGuire</td>
<td>SVP, Comm'l</td>
<td>&gt;25 years of pharma marketing and anti-infectives</td>
</tr>
<tr>
<td>Kevin Conway</td>
<td>VP, Tech Ops</td>
<td>&gt;30 years; operational management of Humira and Kaletra launches</td>
</tr>
<tr>
<td>Kate Farrington</td>
<td>VP, Compliance</td>
<td>&gt;20 years of pharma industry compliance/officer roles</td>
</tr>
</tbody>
</table>
Solid Financial Profile

✓ Sufficient capital to execute key priorities

✓ Significant value inflection points on near-term horizon

✓ Ability to leverage industry-leading infrastructure across multiple assets

✓ Fiscally responsible organization with multiple levers

✓ Sustainable platform for shareholder value generation
## Well-positioned to Meet Critical Unmet Needs

<table>
<thead>
<tr>
<th>Company</th>
<th>Multiple Late-stage Indications</th>
<th>Gram-negative Pipeline</th>
<th>Successful Phase 3 Program</th>
<th>Multiple Approved Products</th>
<th>Sustainable Discovery Capabilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melinta (MLNT)</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
</tr>
<tr>
<td>Achaogen (AKAO)</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td></td>
</tr>
<tr>
<td>Paratek (PRTK)</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td></td>
</tr>
<tr>
<td>Tetraphase (TTPH)</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
</tr>
<tr>
<td>Nabriva (NBRV)</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td>![Checkmark]</td>
<td></td>
</tr>
</tbody>
</table>

Source: Company estimates
Strategy for Long-term Growth and Expansion

**DRIVE**
Sales of >$1 billion from four US-approved antibiotics

**DEVELOP**
Additional indications during 10+ years of market exclusivity for key assets afforded by GAIN Act

**DISCOVER**
Completely novel anti-infectives leveraging our proprietary, Nobel Prize-winning discovery platform

**EXPAND**
Ex-US partnerships across entire product portfolio to enhance company value

*Continue to Execute Growth-accelerating Business Development Activities*
The New Melinta

Four approved antibiotic assets with >$1 billion sales potential
2 on market; 2 launches underway

Robust drug development pipeline to fuel future growth
Global footprint with significant expansion potential

Strong combined experienced talent, processes and capabilities

Nobel prize-winning technology
Proprietary discovery know-how to address emerging resistance

Attractive Growth Equity Story;
Robust Antibiotics Pipeline from Discovery to Commercial;
World-class Capabilities